SCHEMBL4148685

SCHEMBL4148685

O=C1N=C(Nc2c(Cl)cccc2Cl)S/C1=C/c1ccc2nccnc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 4/20 0.53
DYRK1A Q13627 4/20 0.53
DYRK2 Q92630 3/20 0.53
DYRK1B Q9Y463 3/20 0.53
DYRK3 O43781 3/20 0.53
CLK3 P49761 2/20 0.53
CLK4 Q9HAZ1 2/20 0.53
CLK2 P49760 2/20 0.53
CSNK1E P49674 1/20 0.53
GSK3B P49841 1/20 0.53
DYRK4 Q9NR20 1/20 0.53
PIK3CD O00329 3/20 0.48
CSNK2A2 P19784 3/20 0.48
PIK3CA P42336 3/20 0.48
PIK3CG P48736 3/20 0.48
CISD1 Q9NZ45 2/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
CSNK2B P67870 2/20 0.48
CSNK2A1 P68400 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2993704 1.00 CLK1 (0.53) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL2993698 1.00 CLK1 (0.53) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL3393661 0.99 CLK1 (0.52) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL3393655 0.99 CLK1 (0.52) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL3393650 0.99 CLK1 (0.52) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL4641944 0.91 CLK1 (0.48) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL45468 0.91 CLK1 (0.48) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL45467 0.91 CLK1 (0.48) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL4955057 0.90 CLK1 (0.47) CLK1DYRK1ADYRK2DYRK1BDYRK3
SCHEMBL4641199 0.90 CLK1 (0.47) CLK1DYRK1ADYRK2DYRK1BDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888531-A4 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-Ý(2,6-DICHLOROPHENYL)AMINO¨-1,3-THIAZOL-4(5H)-ONE SMITHKLINE BEECHAM CORP (US) 2009-06-17 EP disclosed
EP-1888531-A2 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-Ý(2,6-DICHLOROPHENYL)AMINO¨-1,3-THIAZOL-4(5H)-ONE Smithkline Beecham Corporation (US) 2008-02-20 EP disclosed
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells GLAXOSMITHKLINE LLC 2007-08-02 US disclosed
WO-2006135712-A2 (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE SMITHKLINE BEECHAM CORPORATION (US) 2006-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179144-A1 for treatment of deficiencies in hematopoietic cells HCLS1, HIPK3, HYPK CLK1 523/4885DYRK1A 638/4885DYRK2 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.